藥品製造市場規模、佔有率、成長分析、按配方類型、按給藥途徑、按處方類型、按藥物開發、按分銷管道、按地區 - 行業預測，2025-2032 年

2023年藥品製造市場規模將為5,720.9億美元，從2024年的6,630.5億美元成長到2032年的2,1,588.2億美元，複合年成長率預計將成長15.9%。

由於關鍵的醫療需求以及研究、開發和藥品生產的增加，全球藥品製造市場仍然強勁。關鍵的成長要素包括人口成長、慢性病盛行率上升以及醫療技術的重大進步。對創新藥物、個人化治療和生技藥品的追求正在進一步增強市場活力。此外，擴大醫療基礎設施、旨在改善醫療保健機會的政府舉措以及增加對製造設施的投資正在推動市場成長。然而，該行業面臨嚴格的法律規範、定價壓力和智慧財產權問題等可能阻礙整體進展的挑戰。這種複雜的情況為製藥業相關人員帶來了機會和挑戰。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 監管環境
• 專利分析
• 案例研究
• 客戶和購買標準分析
• 貿易分析

藥品製造市場規模：依配方種類及複合年成長率（2025-2032）

• 市場概況
• 口服製劑
  • 錠劑
  • 膠囊
  • 粉末
• 注射
  • 液體注射
  • 冷凍乾燥注射液
• 局部製劑
  • 奶油
  • 軟膏
  • 凝膠
• 吸入製劑
  • 乾粉吸入器 (DPI)
  • 定量噴霧吸入器(MDI)
• 其他
  • 栓劑
  • 修補

藥品製造市場規模：依管理途徑及複合年成長率（2025-2032）

• 市場概況
• 口服
• 胃腸外的
• 局部的
• 吸入
• 經皮的
• 其他

藥品製造市場規模：依處方種類及複合年成長率（2025-2032）

• 市場概況
• 處方藥
• 非處方藥 (OTC)

藥品製造市場規模：依藥品開發及複合年成長率（2025-2032）

• 市場概況
• 臨床前開發
• 臨床試驗
  • 第一階段
  • 第二階段
  • 第三階段
• 核准
• 商業化生產

藥品製造市場規模：依分銷通路及複合年成長率（2025-2032）

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

藥品製造市場規模：按地區及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Sanofi SA（France）
• Merck & Co., Inc.（USA）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• AstraZeneca plc（UK）
• Eli Lilly and Company（USA）
• AbbVie Inc.（USA）
• Bristol-Myers Squibb Company（USA）
• Bayer AG（Germany）
• Amgen Inc.（USA）
• Gilead Sciences, Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Boehringer Ingelheim GmbH（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Novo Nordisk A/S（Denmark）
• Astellas Pharma Inc.（Japan）
• CSL Limited（Australia）

結論和建議

Pharmaceutical Manufacturing Market size was valued at USD 572.09 Billion in 2023 and is poised to grow from USD 663.05 Billion in 2024 to USD 2158.82 Billion by 2032, growing at a CAGR of 15.9% during the forecast period (2025-2032).

The global pharmaceutical manufacturing market remains robust, driven by essential healthcare demands and a surge in research, development, and drug production. Key growth factors include an increasing population, a rising incidence of chronic diseases, and significant advancements in medical technology. The pursuit of innovative drugs, personalized treatments, and biologics is further enhancing market dynamics. Additionally, the expansion of healthcare infrastructure, government initiatives aimed at improving healthcare access, and rising investments in manufacturing facilities are fueling market growth. Nevertheless, the sector faces challenges such as stringent regulatory frameworks, pricing pressures, and intellectual property rights issues that could hinder overall progress. This complex landscape presents both opportunities and hurdles for stakeholders in the pharmaceutical industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmaceutical Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmaceutical Manufacturing Market Segmental Analysis

Global Pharmaceutical Manufacturing Market is segmented by formulation type, route of administration, prescription type, drug development, distribution channel and region. Based on formulation type, the market is segmented into oral formulations, injectable formulations, topical formulations, inhalation formulations and others. Based on route of administration, the market is segmented into oral, parenteral, topical, inhalation, transdermal and others. Based on prescription type, the market is segmented into prescription drugs and over-the-counter (OTC) drugs. Based on drug development, the market is segmented into preclinical development, clinical trials, regulatory approval and commercial manufacturing. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pharmaceutical Manufacturing Market

A key driver of the global pharmaceutical manufacturing market is the escalating demand for healthcare products and medications across the globe. The expanding global population, combined with a rise in chronic diseases and infectious conditions, has sparked a significant increase in the need for pharmaceuticals. Furthermore, advancements in medical technology and a growing aging demographic further elevate the demand for new and innovative treatments. In response to this escalating market need, pharmaceutical manufacturers are compelled to enhance their production capacities, invest in research and development, and implement cutting-edge manufacturing technologies, ultimately fostering robust market growth.

Restraints in the Pharmaceutical Manufacturing Market

A significant challenge facing the pharmaceutical manufacturing market is the stringent regulatory framework enforced by governments and regulatory agencies. These bodies mandate rigorous standards to ensure the safety, efficacy, and quality of pharmaceutical products, demanding substantial investments in infrastructure, quality assurance processes, and meticulous documentation. Failure to comply with these regulations can lead to severe penalties and tarnish a company's reputation. Additionally, the intricate and lengthy approval process for new drugs can slow down product launches, ultimately delaying access to vital medications for patients. These regulatory hurdles create barriers for new entrants and elevate the overall costs and timelines associated with pharmaceutical manufacturing.

Market Trends of the Pharmaceutical Manufacturing Market

The global pharmaceutical manufacturing market is experiencing a significant trend towards personalized medicine and targeted therapies, fueled by technological advancements in genomics and a demand for individualized treatments. This shift has prompted manufacturers to adapt by embracing smaller batch production and flexible manufacturing processes. Concurrently, the focus on biologics and biosimilars is intensifying due to the growing prevalence of chronic diseases and the pursuit of innovative therapeutic solutions. Sustainability also plays a crucial role, as pharmaceutical companies increasingly prioritize eco-friendly practices, waste reduction, and energy efficiency to comply with stringent environmental regulations and align with evolving consumer expectations.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies
• Customer & Buying Criteria Analysis
• Trade Analysis

Global Pharmaceutical Manufacturing Market Size by Formulation Type & CAGR (2025-2032)

• Market Overview
• Oral Formulations
  • Tablets
  • Capsules
  • Powders
• Injectable Formulations
  • Liquid Injections
  • Lyophilized Injections
• Topical Formulations
  • Creams
  • Ointments
  • Gels
• Inhalation Formulations
  • Dry Powder Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
• Others
  • Suppositories
  • Patches

Global Pharmaceutical Manufacturing Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Topical
• Inhalation
• Transdermal
• Others

Global Pharmaceutical Manufacturing Market Size by Prescription Type & CAGR (2025-2032)

• Market Overview
• Prescription Drugs
• Over-The-Counter (OTC) Drugs

Global Pharmaceutical Manufacturing Market Size by Drug Development & CAGR (2025-2032)

• Market Overview
• Preclinical Development
• Clinical Trials
  • Phase I
  • Phase II
  • Phase III
• Regulatory Approval
• Commercial Manufacturing

Global Pharmaceutical Manufacturing Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Pharmaceutical Manufacturing Market Size & CAGR (2025-2032)

• North America (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • US
  • Canada
• Europe (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations